These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27534398)

  • 1. Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
    Chehade R; Pettapiece-Phillips R; Salmena L; Kotlyar M; Jurisica I; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res; 2016 Aug; 18(1):87. PubMed ID: 27534398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
    Vaclová T; Gómez-López G; Setién F; Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Benítez J; Osorio A
    Breast Cancer Res Treat; 2015 Jul; 152(2):271-82. PubMed ID: 26071757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.
    Pettapiece-Phillips R; Kotlyar M; Chehade R; Salmena L; Narod SA; Akbari M; Jurisica I; Kotsopoulos J
    Cancer Prev Res (Phila); 2016 Jan; 9(1):83-8. PubMed ID: 26526989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
    Tanaka H; Phipps EA; Wei T; Wu X; Goswami C; Liu Y; Sledge GW; Mina L; Herbert BS
    Mol Carcinog; 2018 Apr; 57(4):567-575. PubMed ID: 29240257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.
    Baert A; Depuydt J; Van Maerken T; Poppe B; Malfait F; Storm K; van den Ende J; Van Damme T; De Nobele S; Perletti G; De Leeneer K; Claes KB; Vral A
    Breast Cancer Res; 2016 May; 18(1):52. PubMed ID: 27184744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
    Al-Moghrabi N; Nofel A; Al-Yousef N; Madkhali S; Bin Amer SM; Alaiya A; Shinwari Z; Al-Tweigeri T; Karakas B; Tulbah A; Aboussekhra A
    BMC Cancer; 2014 Nov; 14():830. PubMed ID: 25403427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
    Jernström H; Borg K; Olsson H
    Mol Genet Metab; 2005; 86(1-2):320-7. PubMed ID: 16084122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.
    Abd-Rabbo D; Abaji C; Cardin GB; Filali-Mouhim A; Arous C; Portelance L; Escobar E; Cloutier S; Tonin PN; Provencher DM; Mes-Masson AM; Maugard CM
    Cancer Prev Res (Phila); 2012 May; 5(5):765-77. PubMed ID: 22401979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer.
    Nisman B; Kadouri L; Allweis T; Maly B; Hamburger T; Gronowitz S; Peretz T
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2110-5. PubMed ID: 23966579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency.
    Rennstam K; Ringberg A; Cunliffe HE; Olsson H; Landberg G; Hedenfalk I
    Genes Chromosomes Cancer; 2010 Jan; 49(1):78-90. PubMed ID: 19839046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced?
    van Tilborg TC; Derks-Smeets IA; Bos AM; Oosterwijk JC; van Golde RJ; de Die-Smulders CE; van der Kolk LE; van Zelst-Stams WA; Velthuizen ME; Hoek A; Eijkemans MJ; Laven JS; Ausems MG; Broekmans FJ
    Hum Reprod; 2016 Nov; 31(11):2651-2659. PubMed ID: 27907901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
    Dziaman T; Huzarski T; Gackowski D; Rozalski R; Siomek A; Szpila A; Guz J; Lubinski J; Olinski R
    Int J Cancer; 2009 Nov; 125(9):2209-13. PubMed ID: 19623658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.